Bavarian Nordic Profit Margin 2016-2021 | BVNRY
Current and historical gross margin, operating margin and net profit margin for Bavarian Nordic (BVNRY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bavarian Nordic net profit margin as of June 30, 2021 is -37.43%.
|Bavarian Nordic Annual Profit Margins
|Bavarian Nordic Quarterly Profit Margins
||Medical - Biomedical and Genetics
Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.